FDA grants orphan drug status to Pulmatrix's PUR1900
Thursday, August 18, 2016
Pulmatrix receives orphan drug designation from the FDA for inhaled drug to treat pulmonary fungal infections in cystic fibrosis patients.
FDA granted co's request for orphan drug status for drug for treating pulmonary fungal infections in cystic fibrosis patients, named PUR1900.
Source : reuters.com
